The new era of drug development is powered by digital pathology
Precision medicine strategies rooted in histology now dominate therapeutic pipelines, with next-generation therapies requiring precise, tissue-based digital diagnostics. At the core of this shift is computational pathology, emerging at the forefront of AI-driven strategies to accelerate programs from discovery to commercialization.
To fully harness digital pathology’s transformative potential, life sciences R&D teams need advanced solutions designed to drive innovation at every stage.
Advancements in technology and science have elevated digital pathology’s role in drug development.
Advancing novel therapies from discovery to diagnostics
Advancing novel therapies from discovery to diagnostics
Leading biopharma and biotech organizations leverage Concentriq, Proscia Aperture™, and our precision medicine AI portfolio across the R&D lifecycle to bring treatments to market faster and reach more patients worldwide.
Driving breakthroughs across the life sciences industry
Drug discovery and development teams partner with Proscia to speed up scientific progress, enhance collaboration across teams and partners, and ultimately deliver life-saving therapies and diagnostics to patients faster.
Accelerate R&D at every stage with enterprise-grade solutions that scale
- Increase the speed and accuracy of study reviews and clinical trials with Concentriq’s advanced collaboration tools and AI-powered image analysis workflows
- Build a rich digital data foundation that empowers data science and AI teams to unlock insights and develop AI models, fueling new discoveries
- Augment controlled clinical trial data with diverse, representative real-world data to develop AI-based biomarkers, diagnostics, and pre-screening tools
- Access key global markets through Proscia’s extensive network of diagnostic institutions, streamlining clinical trial site selection, and expanding commercial reach
Be the partner of choice for trusted, innovative drug development
- Accelerate image review cycles and set a new standard for quality with AI-powered workflows that deliver consistent analysis across images and studies
- Share images or entire studies and their associated analyses securely and instantly with internal teams and pharmaceutical sponsors
- Move quickly while meeting compliance standards by ensuring data integrity and traceability are well maintained and submission-ready
- Speed up pathologist recruitment and onboarding with an intuitive, globally-accessible platform, enabling smoother sponsor transitions and faster project starts
Advance high-quality candidates with precision and speed
- Harmonize rich histological, molecular, and spatial datasets to deepen disease understanding and accelerate discovery
- Gain comprehensive tissue insights with intuitive multiplex immunofluorescence workflows powering spatial biology, allowing precise biomarker detection and quantification
- Drive faster, more informed decisions with global search and well-organized data that enables scientists to rapidly ask and answer critical questions
- Discover novel biomarkers and identify therapeutic targets by analyzing complex disease mechanisms with multimodal RWD on the Concentriq platform
FEATURED REPORT
Rewiring Pathology for Precision Drug Discovery and Development
Biopharma leaders are no longer asking if they should invest in digital pathology and AI — they’re scaling it enterprise-wide to accelerate R&D and sharpen their competitive advantage. Through a series of case studies, discover how biopharma companies are using digital pathology and AI to transform precision drug development in five key areas.
Proscia’s solutions advancing therapeutic R&D
With products that uniquely bridge the healthcare and life sciences ecosystems, Proscia empowers R&D teams with clinically relevant data to fuel the discovery of novel therapies, diagnostics, and AI-based biomarkers, and enables these innovations to reach more patients.
The solutions driving these advancements in life sciences include our enterprise pathology platform, real-world data, and AI offerings.
Concentriq Platform
Concentriq LS is the enterprise pathology platform for life sciences that serves as the central hub for AI-enabled scientific workflows, unifying data, teams, and applications to power image-based research from discovery to early clinical development.
The Concentriq AP-Dx platform, which features regulated components for diagnostic use, advances late-stage clinical trials and provides an accelerated pathway to deployment of novel diagnostics and therapies through Proscia’s global lab network.
Proscia Aperture™
Transform routine diagnoses into actionable intelligence with Aperture. Powered by Proscia’s global network of diagnostic labs reviewing 8 million cases annually on the Concentriq enterprise pathology platform, Proscia Aperture is a precision medicine solution that surfaces patient insights at the moment of diagnosis. Teams using Aperture can advance discovery and translational research, accelerate trial enrollment, and generate real-time evidence for market access strategies.
AI Portfolio
Run leading AI applications with image analysis workflows to optimize quality control, toxicity assessments, patient stratification, and more.
Develop high-performing AI models 13x faster with Concentriq Embeddings by seamlessly transforming large datasets into AI-ready representations using state-of-the-art foundation models directly within the Concentriq platform.
Build more AI models, faster with Concentriq
With Concentriq Embeddings — Proscia’s pathology foundation model API — data science and AI teams within life sciences organizations are rapidly building high-performing AI algorithms at scale to advance precision medicine portfolios.
Discover how Proscia’s AI R&D team leveraged Concentriq Embeddings to build 80 breast cancer biomarker prediction models in under 24 hours.
Proscia Named to 2025 Fierce 15
Proscia earned its spot for AI pathology leadership across the precision medicine value chain, and making an outsized impact on healthcare. Find out why Concentriq is trusted by 16 of the top 20 pharmaceutical companies.
“Proscia’s Concentriq Platform is helping us drive value. We can combine all of our different image analyses under one roof, which I thought was a huge benefit. You can start to establish a common practice within images or pathology data.”
Principal Scientist
Learn more about Proscia’s solutions for life sciences
Learn more about Proscia’s solutions for life sciences
Webinar
IQVIA Laboratories: Streamlining Clinical Development and Maximizing Trial Success with an Enterprise Pathology Platform
Webinar
Bioptimus and Proscia: Unlocking the Promise of Foundation Models in Pathology for AI-Driven Drug Discovery and Development
Poster
Bayer: Real-Time Messaging of Pathological Diagnoses from Toxicology LIMS to Cloud-Based Digital Pathology Web Application
Study Report
Rewiring Pathology for Precision Drug Discovery and Development: A scientific review of the evidence behind digital pathology and AI’s transformative role in biopharma R&D
Discover how Proscia can accelerate your therapeutic development programs
Connect with a life sciences digital pathology expert today to explore how Proscia can help your organization tackle modern R&D’s biggest challenges.